Skip to main content
SpringerLink
Log in

Idiopathic Chronic Immune-Mediated Neuropathies: Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy

  • Chapter
  • First Online:
Acquired Neuromuscular Disorders

  • 509 Accesses

Abstract

Chronic immune-mediated neuropathies are a rather heterogeneous group of disorders of the peripheral nervous system deemed to be caused by an autoimmune attack against peripheral nerves. They include idiopathic disorders where the disease only involves peripheral nerve such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) or may be the consequence of other disease that causes the production of antibodies against nerve such as neuropathies associated with monoclonal gammopathy or paraneoplastic neuropathies. The spreading interest on these neuropathies is derived from the fact that most affected patients can be treated successfully with immune therapies that differ however from disease to disease highlighting the need for a correct diagnosis. We will here review the clinical, pathogenetic, and therapeutic aspects of the two main forms of idiopathic immune-mediated neuropathies, CIDP and MMN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vallat J-M, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9:402–12.

    Article  PubMed  Google Scholar 

  2. Hughes RAC, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006;11:30–46.

    Article  PubMed  Google Scholar 

  3. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy: where we are, where we should go. J Peripher Nerv Syst. 2014;19:2–13.

    Article  CAS  PubMed  Google Scholar 

  4. Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tattori Prefecture, Japan. Psychiatry Clin Neurosci. 1995;49:169–74.

    Article  CAS  PubMed  Google Scholar 

  5. Laughlin RS, Dyck PJ, Melton LJ 3rd, et al. Incidence and prevalence of CIDP and the associations with diabetes mellitus. Neurology. 2009;73:39–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39:432–8.

    Article  PubMed  Google Scholar 

  7. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973–85. pii: jnnp-2014-309697. https://doi.org/10.1136/jnnp-2014-309697.

    Article  PubMed  Google Scholar 

  8. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90:125–32.

    Article  PubMed  Google Scholar 

  9. Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology. 2010;74:1680–6.

    Article  CAS  PubMed  Google Scholar 

  10. Lunn MPT, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in southeast England. J Neurol Neurosurg Psychiatry. 1999;66:677–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chiò A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78:1349–53.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Oh SJ, Joy JL, Kuruoglu R. “Chronic sensory demyelinating neuropathy:” chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992;55:677–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ayrignac X, Viala K, Morizot Koutlidis R, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013;48:727–32.

    Article  PubMed  Google Scholar 

  14. Sinnreich M, Klein CJ, Daube JR, et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology. 2004;63:1662–9.

    Article  CAS  PubMed  Google Scholar 

  15. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982;32:958–64.

    Article  CAS  PubMed  Google Scholar 

  17. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain. 1996;119:765–74.

    Article  PubMed  Google Scholar 

  18. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615–20.

    Article  CAS  PubMed  Google Scholar 

  19. Nobile-Orazio E. Neuropathy and monoclonal gammopathy. In: Said G, Krarup C, editors. Handbook of clinical neurology, vol. 115 (3rd series), Peripheral nerve disorders. Amsterdam: Elsevier BV. 2013. pp. 443–59.

    Google Scholar 

  20. Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2006;13:326–32.

    Article  CAS  PubMed  Google Scholar 

  21. Doneddu PE, Cocito D, Manganelli F, et al. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020;91(10):1092–9.

    Article  PubMed  Google Scholar 

  22. Rajabally YA, Peric S, Cobeljic M, et al. Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal. J Neurol Neurosurg Psychiatry. 2020;91:1100–4.

    Article  PubMed  Google Scholar 

  23. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibody to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013;73:370–80.

    Article  CAS  PubMed  Google Scholar 

  24. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82:879–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 2015;138(Pt 6):1484–91. pii: awv054. [Epub ahead of print].

    Article  PubMed  PubMed Central  Google Scholar 

  26. Doneddu PE, Bianchi E, Cocito D, et al. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP database. Eur J Neurol. 2020;27:136–43.

    Article  CAS  PubMed  Google Scholar 

  27. Doneddu PE, Bianchi E, Cocito D, et al. Impact of environmental factors and physical activity on disability and quality of life in CIDP. J Neurol. 2020;267(9):2683–91.

    Article  PubMed  Google Scholar 

  28. Blum S, McCombe PA. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst. 2014;19:88–103.

    Article  CAS  PubMed  Google Scholar 

  29. Martinez-Martinez L, Lleixà MC, Boera-Carnicero G, et al. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. J Neuroinflammation. 2017;14:224.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85:498–504.

    Article  CAS  PubMed  Google Scholar 

  31. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst. 2010;15:1–9.

    Article  Google Scholar 

  32. Breiner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2013;50:40–6.

    Article  PubMed  Google Scholar 

  33. Liberatore G, Manganelli F, Cocito D, et al. Relevance of diagnostic investigations in chronic inflammatory demyelinating polyradiculoneuropathy: data from the Italian CIDP database. J Peripher Nerv Syst. 2020. https://doi.org/10.1111/jns.12378.

  34. Liberatore G, Manganelli F, Doneddu PE, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: can we make a diagnosis in patients not fulfilling electrodiagnostic criteria? Eur J Neurol. 2021;28(2):620–9. https://doi.org/10.1111/ene.14545.

    Article  CAS  PubMed  Google Scholar 

  35. Herraets IJT, Goedee HS, Telleman JA, et al. Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology. 2020;94:e1470–9.

    Article  CAS  PubMed  Google Scholar 

  36. Herraets IJT, Goedee HS, Telleman JA, et al. Nerve ultrasound for diagnosing chronic inflammatory neuropathy: a multicenter validation study. Neurology. 2020;95:e1745–53.

    Article  CAS  PubMed  Google Scholar 

  37. Goedee HS, Herraets IJT, Visser LH, et al. Nerve ultrasound can identify treatment-responsive chronic neuropathies without electrodiagnostic features of demyelination. Muscle Nerve. 2019;60:415–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;1:CD002062.

    PubMed  Google Scholar 

  39. Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2012;9:CD003906.

    Google Scholar 

  40. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:CD001797.

    Google Scholar 

  41. Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17:289–94.

    Article  CAS  PubMed  Google Scholar 

  42. Hughes RAC, Bensa S, Willison HJ, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.

    Article  CAS  PubMed  Google Scholar 

  43. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–45.

    Article  CAS  PubMed  Google Scholar 

  44. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502.

    Article  CAS  PubMed  Google Scholar 

  45. Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86:729–34.

    Article  PubMed  Google Scholar 

  46. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2020;9:245–53.

    Article  Google Scholar 

  47. Doneddu PE, Mandia D, Gentile F, et al. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25:238–46.

    Article  CAS  PubMed  Google Scholar 

  48. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46.

    Article  PubMed  Google Scholar 

  49. van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6:e590.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33:984–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Cocito D, Merola A, Peci E, et al. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. J Neurol. 2014;261:2159–64.

    Article  CAS  PubMed  Google Scholar 

  52. Cocito D, Merola A, Romagnolo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry. 2016;87:791–3.

    Article  PubMed  Google Scholar 

  53. Markvardsen LH, Harbo T, Sindrup SH, et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2014;21:1465–70.

    Article  CAS  PubMed  Google Scholar 

  54. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;(6):CD003280.

    Google Scholar 

  55. Hughes R, Dalakas MC, Merkies I, et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018;17:689–98.

    Article  CAS  PubMed  Google Scholar 

  56. Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Jiao L, Xiang Y, Li S, Zhang F, Ruan X, Guo S. Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. J Neuroimmunol. 2020;345:577280.

    Article  CAS  PubMed  Google Scholar 

  58. Benedetti L, Briani C, Franciotta D, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82:306–8.

    Article  CAS  PubMed  Google Scholar 

  59. Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;61:575–9.

    Article  PubMed  Google Scholar 

  60. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.

    Article  CAS  PubMed  Google Scholar 

  61. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663–80.

    Article  PubMed  Google Scholar 

  62. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, et al. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–19.

    Article  PubMed  Google Scholar 

  63. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in Southeast England. Eur J Neurol. 2014;21:28–33.

    Article  CAS  PubMed  Google Scholar 

  64. Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88:304–13.

    Article  PubMed  Google Scholar 

  65. Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75:818–25.

    Article  CAS  PubMed  Google Scholar 

  66. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. First revision. J Peripher Nerv Syst. 2010;15:295–301.

    Article  Google Scholar 

  67. Herraets I, van Rosmalen M, Bos J, et al. Clinical outcomes in multifocal motor neuropathy: a combined cross-sectional and follow-up study. Neurology. 2020;95(14):e1979–87. https://doi.org/10.1212/WNL.0000000000010538.

    Article  PubMed  Google Scholar 

  68. Martinez-Thompson JM, Snyder MR, et al. Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM. Muscle Nerve. 2018;57:1000–5.

    Article  CAS  PubMed  Google Scholar 

  69. Nobile-Orazio E, Giannotta C, Musset L, et al. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014;85:754–8.

    Article  PubMed  Google Scholar 

  70. Oudeman J, Eftimov F, Strijkers GJ, et al. Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology. 2019;94:e62–74.

    Article  PubMed  Google Scholar 

  71. Riva N, Iannaccone S, Corbo M, et al. Motor nerve biopsy: clinical usefulness and histopathological criteria. Ann Neurol. 2011;69:197–201.

    Article  PubMed  Google Scholar 

  72. Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol. 1995;38:111–8.

    Article  CAS  PubMed  Google Scholar 

  73. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;2:CD004429.

    Google Scholar 

  74. Kuwabara S, Misawa S, Mori M, et al. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: a multi-center, open-label, 52-week phase 3 trial. J Peripher Nerv Syst. 2018;23:115–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Van den Berg-Vos RM, Franssen H, Wokke JHJ, et al. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002;125:1875–86.

    Article  PubMed  Google Scholar 

  76. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology. 2004;62:666–8.

    Article  CAS  PubMed  Google Scholar 

  77. Löscher WN, Oberreiter EM, Erdler M, et al. Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment. J Neurol. 2018;265:2834–40.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single–blinded cross-over trial. Eur J Neurol. 2009;16:631–8.

    Article  CAS  PubMed  Google Scholar 

  79. Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93–100.

    Article  CAS  PubMed  Google Scholar 

  80. Katzberg HD, Rasutis V, Bril V. Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy. Muscle Nerve. 2016;54:856–63.

    Article  CAS  PubMed  Google Scholar 

  81. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology. 2010;75:1377–80.

    Article  CAS  PubMed  Google Scholar 

  82. Umapathi T, Hughes R, Nobile-Orazio E, Leger J. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2015;3:CD003217.

    Google Scholar 

  83. Meucci N, Cappellari A, Barbieri S, et al. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997;63:765–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196–201.

    Article  CAS  PubMed  Google Scholar 

  85. Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, Milan, Italy

    Pietro Emiliano Doneddu, Giuseppe Liberatore, Francesca Gallia & Eduardo Nobile-Orazio

  2. Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center—IRCCS, Rozzano, Milan, Italy

    Pietro Emiliano Doneddu, Giuseppe Liberatore, Francesca Gallia & Eduardo Nobile-Orazio

Authors
  1. Pietro Emiliano Doneddu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Liberatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca Gallia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eduardo Nobile-Orazio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Nobile-Orazio .

Editor information

Editors and Affiliations

  1. Department Neurosciences, Neuromuscular Center, Campus Pietro d’Abano, University of Padova, Padova, Padova, Italy

    Corrado Angelini

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Doneddu, P.E., Liberatore, G., Gallia, F., Nobile-Orazio, E. (2022). Idiopathic Chronic Immune-Mediated Neuropathies: Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy. In: Angelini, C. (eds) Acquired Neuromuscular Disorders. Springer, Cham. https://doi.org/10.1007/978-3-031-06731-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-06731-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-06730-3

  • Online ISBN: 978-3-031-06731-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation